Spyre Therapeutics, LLC

Spyre Therapeutics granted 21,000 stock options to a non-executive employee under its 2018 Equity Inducement Plan, with a 10-year term and $24.35 exercise price, vesting over time. The company focuses on innovative treatments for Inflammatory Bowel Disease using advanced biotechnology approaches.

The article content is not provided or is empty, making it impossible to summarize.

Spyre Therapeutics, Inc. has been added to the Nasdaq Biotechnology Index, effective December 23, 2024. The company utilizes best-in-class antibody engineering and precision medicine for IBD treatment.